Andrew Nava's  Instablog

Andrew Nava
Send Message
Andrew Nava LLC is a healthcare focused consulting and investment firm. Prior to launching Andrew Nava LLC, I was a venture analyst, buy-side analyst, and most recently, the Director of Research at Actin Biomed, a New York-based healthcare investment firm where I was responsible for the medical,... More
My company:
Andrew Nava, LLC
  • Morning Note to Clients Oct 4, 2010: New Milestones and Updates at AndrewNava.com 0 comments
    Oct 4, 2010 8:41 AM | about stocks: ACHN, AMGN, ENDP, GSK, OPTR, PGNX, RPRX

    Below is a sample email sent out to clients of AndrewNava.com.  The email briefly lists new milestones added to AndrewNava.com as well as several new database updates, including updated financial and clinical data.

    Dear Client,

    Here are the latest updates at AndrewNava.com...

    NEW MILESTONES:

    ACHN: 28-day and 12-week phase 2 data expected in 1Q11 and 4Q11, respectively, from ACH-1625.
    AMGN:
    Renal/CV AdComm to discuss Aranesp TREAT Study 10/18/10.
    ENDP:
    Oxymorphone new formulation PDUFA Jan. 7, 2011.
    HGSI:
    Benlysta Arthritis AdComm 11/16/10.
    OPTR:
    Fidaxomicin rolling NDA filed 9/21/10 with expected approval March 21, 2011 (will request priority review).
    PGNX:
    Relistor subcutaneous sNDA filing expected 1H11 (chronic pain OIC), pre-filled syringe (8 and 12 mg) launch expected 1H11.
    RPRX:
    Type B meeting on November 8, 2010 with the FDA Division of Reproductive and Urologic Products to review Androxal Phase III pivotal trial protocols.
    ZLCS:
    Prednisporin (FOV1101) data expected YE10 from Sanofi-Aventis (Fovea) persistant allergic conjunctivitis study.

    DATABASE UPDATES: ETRM, CXM, CLSN, PPHM, ANTH, CPRX, ACCP, VRX, BIIB, NNVC, VICL, BSDM, RIGL, ENDP, CHTP, SNSS, EBS, XOMA, DYAX, AVEO, CERS, YMI (financials), ALNY, tesetaxel, ONTY, PTN, ICO, CORX, OGX-427, APRI.


    For full milestones, clinical trial data, and drug sales, please visit
    http://andrewnava.com

    Andrew Nava, LLC provides institutional and retail healthcare investors with buy-side equity research tools which focus on value-driven investing, profitable trading ideas and clinical, commercial, and regulatory catalysts. Our research is supported by consulting with KOL's, industry professionals, company management, and our database of clinical trial data and upcoming company milestones.

    Disclosure: No positions

    Disclosure: No positions

    Stocks: ACHN, AMGN, ENDP, GSK, OPTR, PGNX, RPRX
Back To Andrew Nava's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.